Skip to main content

NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New Synergy Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGYP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGYP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
This price target is based on 0 analysts offering 12 month price targets for Synergy Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Synergy Pharmaceuticals. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/26/2018Canaccord GenuityDowngradeBuy ➝ HoldN/A
i
10/26/2018BTIG ResearchDowngradeBuy ➝ NeutralN/A
i
Rating by Tim Chiang at BTIG Research
8/7/2018HC WainwrightReiterated RatingBuy$7.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/24/2018Cantor FitzgeraldReiterated RatingHoldHigh
i
6/6/2018HC WainwrightSet Price TargetBuy$7.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/14/2018BTIG ResearchSet Price TargetBuy$7.00Low
i
Rating by Tim Chiang at BTIG Research
5/13/2018HC WainwrightSet Price TargetBuy$7.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/13/2018OppenheimerReiterated RatingHoldLow
i
Rating by Christopher Liu at Oppenheimer Holdings Inc.
5/7/2018HC WainwrightSet Price TargetBuy$7.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/22/2018OppenheimerReiterated RatingHoldLow
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
3/5/2018HC WainwrightSet Price TargetBuy$7.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
3/1/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
2/1/2018HC WainwrightReiterated RatingBuy$7.00High
i
Rating by Ram Selvaraju at HC Wainwright
2/1/2018Cantor FitzgeraldReiterated RatingBuyHigh
i
Rating by W. Tanner at Cantor Fitzgerald
1/25/2018Cantor FitzgeraldReiterated RatingBuy$10.00High
i
Rating by W. Tanner at Cantor Fitzgerald
1/22/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
1/8/2018HC WainwrightSet Price TargetBuy$7.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
1/5/2018OppenheimerReiterated RatingOutperform ➝ Market Perform$10.00High
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
1/5/2018CIBCReiterated RatingOutperform ➝ Market PerformHigh
i
1/5/2018CitigroupDowngradeMarket PerformHigh
i
1/4/2018OppenheimerDowngradeOutperform ➝ Market PerformHigh
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
12/4/2017HC WainwrightSet Price TargetBuy$7.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/21/2017Cantor FitzgeraldReiterated RatingBuy$10.00N/A
i
Rating by W. Tanner at Cantor Fitzgerald
11/14/2017BTIG ResearchReiterated RatingBuy$7.00N/A
i
11/12/2017Canaccord GenuitySet Price TargetBuy$13.00N/A
i
Rating by John Newman at Canaccord Genuity
10/18/2017HC WainwrightSet Price TargetBuy$8.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
10/11/2017HC WainwrightSet Price TargetBuy$8.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
10/10/2017OppenheimerSet Price TargetBuy$6.00N/A
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
9/25/2017HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $8.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/13/2017CitigroupReiterated RatingSell ➝ Sell$3.20 ➝ $2.50Medium
i
9/8/2017BTIG ResearchReiterated RatingBuy$11.00Medium
i
9/8/2017CIBCLower Price TargetOutperform ➝ Outperform$9.00 ➝ $6.00Low
i
9/8/2017Cantor FitzgeraldReiterated RatingOverweight$11.00Medium
i
Rating by W. Tanner at Cantor Fitzgerald
9/8/2017OppenheimerLower Price TargetOutperform$9.00 ➝ $6.00Medium
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
8/10/2017Rodman & RenshawLower Price TargetBuy ➝ Buy$18.00 ➝ $15.00High
i
8/10/2017HC WainwrightSet Price TargetBuy$15.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/10/2017OppenheimerSet Price TargetBuy$9.00High
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
8/10/2017Cantor FitzgeraldReiterated RatingBuy$11.00High
i
7/31/2017Canaccord GenuitySet Price TargetBuy$13.00Low
i
Rating by John Newman at Canaccord Genuity
7/18/2017OppenheimerReiterated RatingOutperform$9.00Low
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
7/10/2017Canaccord GenuityReiterated RatingBuy$13.00Low
i
Rating by John Newman at Canaccord Genuity
6/28/2017CitigroupReiterated RatingSell$3.70Low
i
6/27/2017BTIG ResearchReiterated RatingBuy$11.00High
i
6/14/2017Rodman & RenshawReiterated RatingBuy$18.00Medium
i
6/12/2017HC WainwrightReiterated RatingBuy$18.00Low
i
Rating by Ram Selvaraju at HC Wainwright
6/9/2017Cantor FitzgeraldReiterated RatingOverweight$11.00Low
i
6/1/2017Cantor FitzgeraldInitiated CoverageOverweight$11.00High
i
5/31/2017BTIG ResearchReiterated RatingBuy$11.00Low
i
5/23/2017Rodman & RenshawReiterated RatingBuy$18.00High
i
5/19/2017HC WainwrightReiterated RatingBuy$18.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/19/2017Canaccord GenuityReiterated RatingBuy$13.00Low
i
Rating by John Newman at Canaccord Genuity
5/10/2017OppenheimerSet Price TargetBuy$10.00 ➝ $9.00Medium
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
4/22/2017BTIG ResearchReiterated RatingBuy$11.00Low
i
4/11/2017BTIG ResearchReiterated RatingBuy$11.00Low
i
4/6/2017CitigroupDowngradeNeutral ➝ SellHigh
i
3/29/2017Rodman & RenshawReiterated RatingBuy$18.00Low
i
3/28/2017HC WainwrightReiterated RatingBuy$18.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
3/21/2017BTIG ResearchReiterated RatingBuy$11.00Low
i
3/16/2017HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/3/2017Rodman & RenshawReiterated RatingBuy$18.00N/A
i
3/2/2017OppenheimerSet Price TargetBuy$10.00N/A
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
3/2/2017Canaccord GenuitySet Price TargetBuy$13.00N/A
i
Rating by John Newman at Canaccord Genuity
3/2/2017GuggenheimReiterated RatingOutperform$10.00N/A
i
1/31/2017OppenheimerReiterated RatingOutperform$10.00N/A
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
1/28/2017Canaccord GenuityReiterated RatingBuy$13.00N/A
i
Rating by John Newman at Canaccord Genuity
1/27/2017HC WainwrightSet Price TargetBuy$18.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
1/26/2017BTIG ResearchReiterated RatingPositive$11.00N/A
i
1/21/2017Canaccord GenuitySet Price TargetBuy$13.00N/A
i
Rating by John Newman at Canaccord Genuity
1/21/2017OppenheimerSet Price TargetBuy$10.00N/A
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
1/20/2017BTIG ResearchReiterated RatingBuy$11.00N/A
i
1/20/2017Rodman & RenshawBoost Price TargetBuy$17.00 ➝ $18.00N/A
i
1/4/2017OppenheimerInitiated CoverageOutperform$10.00N/A
i
12/31/2016Rodman & RenshawBoost Price TargetBuy$16.00 ➝ $17.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
12/23/2016Canaccord GenuityReiterated RatingBuy$13.00N/A
i
Rating by John Newman at Canaccord Genuity
12/23/2016Rodman & RenshawBoost Price TargetBuy$16.00 ➝ $17.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
12/23/2016BTIG ResearchReiterated RatingBuy$11.00N/A
i
12/15/2016Roth CapitalReiterated RatingBuy$6.50N/A
i
12/13/2016Rodman & RenshawReiterated RatingBuy$15.00 ➝ $16.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
12/12/2016HC WainwrightSet Price TargetBuy$16.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
12/9/2016Canaccord GenuitySet Price TargetBuy$13.00N/A
i
Rating by John Newman at Canaccord Genuity
12/6/2016BTIG ResearchReiterated RatingBuy$11.00N/A
i
11/30/2016Rodman & RenshawReiterated RatingBuy$15.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
11/14/2016Canaccord GenuityReiterated RatingBuy$13.00N/A
i
Rating by John Newman at Canaccord Genuity
11/11/2016Rodman & RenshawReiterated RatingBuy$15.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
10/24/2016HC WainwrightSet Price TargetBuy$15.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
10/21/2016Canaccord GenuityReiterated RatingBuy$13.00N/A
i
Rating by John Newman at Canaccord Genuity
10/17/2016BTIG ResearchReiterated RatingPositive$11.00N/A
i
9/16/2016BTIG ResearchReiterated RatingBuy$11.00N/A
i
Rating by Tim Chiang at BTIG Research
9/8/2016HC WainwrightSet Price TargetBuy$15.00N/A
i
Rating by ram selvaraju at HC Wainwright
9/8/2016Rodman & RenshawReiterated RatingBuy$15.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
8/25/2016BTIG ResearchInitiated CoverageBuy$11.00N/A
i
Rating by Tim Chiang at BTIG Research
8/13/2016Rodman & RenshawReiterated RatingBuy$15.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
7/19/2016BTIG ResearchReiterated RatingBuy$11.00N/A
i
Rating by Tim Chiang at BTIG Research
7/17/2016Canaccord GenuityReiterated RatingBuy$13.00N/A
i
Rating by John Newman at Canaccord Genuity
7/12/2016Rodman & RenshawReiterated RatingBuy$15.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
5/26/2016Roth CapitalReiterated RatingBuy$6.50N/A
i
Rating by Michael Higgins at Roth Capital
5/23/2016Rodman & RenshawReiterated RatingBuy$15.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
5/23/2016BTIG ResearchReiterated RatingBuy$11.00N/A
i
Rating by Tim Chiang at BTIG Research
5/23/2016Canaccord GenuityReiterated RatingBuy$13.00N/A
i
5/9/2016Roth CapitalReiterated RatingBuyN/A
i
Rating by Michael Higgins at Roth Capital
5/9/2016Rodman & RenshawLower Price TargetBuy$16.00 ➝ $15.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
(Data available from 5/8/2016 forward)
Synergy Pharmaceuticals logo
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.02
$0.01
$0.03

52 Week Range

Now: N/A

Volume

N/A

Average Volume

6,081,307 shs

Market Capitalization

$7.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Synergy Pharmaceuticals?

The following equities research analysts have issued research reports on Synergy Pharmaceuticals in the last twelve months:
View the latest analyst ratings for SGYP.

What is the current price target for Synergy Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Synergy Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Synergy Pharmaceuticals in the next year.
View the latest price targets for SGYP.

What is the current consensus analyst rating for Synergy Pharmaceuticals?

Synergy Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SGYP.

What other companies compete with Synergy Pharmaceuticals?

How do I contact Synergy Pharmaceuticals' investor relations team?

Synergy Pharmaceuticals' physical mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company's listed phone number is 212-297-0020 and its investor relations email address is [email protected] The official website for Synergy Pharmaceuticals is www.synergypharma.com.